

Renaud Du Pasquier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3729731/publications.pdf>

Version: 2024-02-01

136
papers

7,456
citations

71102

41
h-index

56724

83
g-index

139
all docs

139
docs citations

139
times ranked

10312
citing authors

#	ARTICLE	IF	CITATIONS
1	Intrinsic blood-brain barrier dysfunction contributes to multiple sclerosis pathogenesis. <i>Brain</i> , 2022, 145, 4334-4348.	7.6	37
2	Neurodegenerative phagocytes mediate synaptic stripping in Neuro-HIV. <i>Brain</i> , 2022, 145, 2730-2741.	7.6	7
3	Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. <i>Lancet Neurology</i> , The, 2022, 21, 246-257.	10.2	210
4	Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis. <i>JAMA Neurology</i> , 2022, 79, 682.	9.0	41
5	First-ever treatment in multiple sclerosis. <i>Revue Neurologique</i> , 2021, 177, 93-99.	1.5	0
6	Pattern of cognitive deficits in severe COVID-19. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 567-568.	1.9	108
7	Is disease activity prior to fingolimod initiation predictive of response? Fingolimod as a common first line treatment. <i>Revue Neurologique</i> , 2021, 177, 935-940.	1.5	2
8	The association between depressive symptoms and neurocognitive impairment in people with well-treated HIV in Switzerland. <i>International Journal of STD and AIDS</i> , 2021, 32, 729-739.	1.1	5
9	Alcohol consumption and neurocognitive deficits in people with well-treated HIV in Switzerland. <i>PLoS ONE</i> , 2021, 16, e0246579.	2.5	3
10	Unexpected worsening of progressive multifocal leucoencephalopathy following COVID-19 pneumonia. <i>Journal of NeuroVirology</i> , 2021, 27, 510-513.	2.1	4
11	Case Report: Behavioral Unresponsiveness in Acute COVID-19 Patients: The Utility of the Motor Behavior Tool-Revised and 18F-FDG PET/CT. <i>Frontiers in Neurology</i> , 2021, 12, 644848.	2.4	5
12	Anti-Adenylate Kinase 5 Encephalitis With Histologic Evidence of CNS Vasculitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, e1010.	6.0	2
13	Recurrence of disease activity after fingolimod discontinuation in older patients previously stable on treatment. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 51, 102918.	2.0	11
14	Discussing Challenges in Diagnosis of Tuberculous Meningitis and Neurosarcoidosis. <i>Canadian Journal of Neurological Sciences</i> , 2021, , 1-7.	0.5	0
15	Encephalopathies Associated With Severe COVID-19 Present Neurovascular Unit Alterations Without Evidence for Strong Neuroinflammation. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	34
16	Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e543-e553.	1.1	54
17	Neurocognitive course at two-year follow-up in the neurocognitive assessment in the metabolic and aging cohort (NAMACO) study. <i>Aids</i> , 2021, Publish Ahead of Print, 2469-2480.	2.2	6
18	Advances in Treatment of Progressive Multifocal Leukoencephalopathy. <i>Annals of Neurology</i> , 2021, 90, 865-873.	5.3	18

#	ARTICLE	IF	CITATIONS
19	Differentiation of functional astrocytes from human-induced pluripotent stem cells in chemically defined media. STAR Protocols, 2021, 2, 100902.	1.2	11
20	The "central vein sign" in patients with diagnostic "red flags" for multiple sclerosis: A prospective multicenter 3T study. Multiple Sclerosis Journal, 2020, 26, 421-432.	3.0	44
21	Self-reported Neurocognitive Impairment in People Living With Human Immunodeficiency Virus (HIV): Characterizing Clusters of Patients With Similar Changes in Self-reported Neurocognitive Impairment, 2013-2017, in the Swiss HIV Cohort Study. Clinical Infectious Diseases, 2020, 71, 637-644.	5.8	3
22	Evolution of Cortical and White Matter Lesion Load in Early-Stage Multiple Sclerosis: Correlation With Neuroaxonal Damage and Clinical Changes. Frontiers in Neurology, 2020, 11, 973.	2.4	8
23	RimNet: A deep 3D multimodal MRI architecture for paramagnetic rim lesion assessment in multiple sclerosis. NeuroImage: Clinical, 2020, 28, 102412.	2.7	21
24	Vaccine-associated measles in a patient treated with natalizumab: a case report. BMC Infectious Diseases, 2020, 20, 753.	2.9	8
25	Meningeal Relapse of Nodular Lymphocyte Predominant Hodgkin Lymphoma Transformed to T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Case Report. Frontiers in Oncology, 2020, 10, 1745.	2.8	1
26	Clinical Reasoning: A 69-year-old man with rare complex visual symptoms. Neurology, 2020, 95, 316-320.	1.1	0
27	Vaccination in B-cell-depleted patients with multiple sclerosis. Neurology, 2020, 95, 613-614.	1.1	5
28	Paramagnetic Rim Lesions are Specific to Multiple Sclerosis: An International Multicenter 3T MRI Study. Annals of Neurology, 2020, 88, 1034-1042.	5.3	89
29	Advancing human induced pluripotent stem cell-derived blood-brain barrier models for studying immune cell interactions. FASEB Journal, 2020, 34, 16693-16715.	0.5	47
30	Progressive multifocal leukoencephalopathy responsive to withdrawal of imatinib in a patient with FIP1L1-PDGFR α positive myeloid neoplasm. Leukemia and Lymphoma, 2020, 61, 2226-2229.	1.3	1
31	Authors' reply to A. Winston, A. Cotter, M. Gisslen, P. W. G. Mallon and P. Cinque. HIV Medicine, 2020, 21, e19-e20.	2.2	1
32	Two patients with acute meningoencephalitis concomitant with SARS-CoV-2 infection. European Journal of Neurology, 2020, 27, e43-e44.	3.3	149
33	CVSnet: A machine learning approach for automated central vein sign assessment in multiple sclerosis. NMR in Biomedicine, 2020, 33, e4283.	2.8	31
34	Human Leukocyte Antigen Genotype as a Marker of Multiple Sclerosis Prognosis. Canadian Journal of Neurological Sciences, 2020, 47, 189-196.	0.5	4
35	Motor behavior unmasking residual cognition in disorders of consciousness. Annals of Neurology, 2019, 85, 443-447.	5.3	40
36	Specific aspects of immunotherapy for multiple sclerosis in Switzerland: A structured commentary. Clinical and Translational Neuroscience, 2019, 3, 2514183X1882207.	0.9	5

#	ARTICLE	IF	CITATIONS
37	Reader response: Progressive multifocal leukoencephalopathy after fingolimod treatment. <i>Neurology</i> , 2019, 92, 151-151.	1.1	6
38	Cross-Sectional and Cumulative Longitudinal Central Nervous System Penetration Effectiveness Scores Are Not Associated With Neurocognitive Impairment in a Well Treated Aging Human Immunodeficiency Virus-Positive Population in Switzerland. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz277.	0.9	20
39	Efficacy of Natalizumab in Intermediate Uveitis Related to Multiple Sclerosis: A Case Report. <i>Klinische Monatsblätter Für Augenheilkunde</i> , 2018, 235, 476-477.	0.5	6
40	Natalizumab may control immune checkpoint inhibitor-induced limbic encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e439.	6.0	87
41	Exploring the effect of vitamin D ³ supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1280-1287.	3.0	32
42	A Swiss neurological paradox. <i>Clinical and Translational Neuroscience</i> , 2018, 2, 2514183X1878525.	0.9	0
43	Effect of national HIV testing recommendations and local interventions on HIV testing practices in a Swiss university hospital: a retrospective analysis between 2012 and 2015. <i>BMJ Open</i> , 2018, 8, e021203.	1.9	0
44	Late Lyme neuroborreliosis with chronic encephalomyelitis. <i>Neurology</i> , 2018, 91, 627-628.	1.1	6
45	Human Induced Pluripotent Stem Cell-Derived Astrocytes Are Differentially Activated by Multiple Sclerosis-Associated Cytokines. <i>Stem Cell Reports</i> , 2018, 11, 1199-1210.	4.8	114
46	Determination of nucleosidic/tidic reverse transcriptase inhibitors in plasma and cerebrospinal fluid by ultra-high-pressure liquid chromatography coupled with tandem mass spectrometry. <i>Clinical Mass Spectrometry</i> , 2018, 8, 8-20.	1.9	10
47	EBI2 Expression and Function: Robust in Memory Lymphocytes and Increased by Natalizumab in Multiple Sclerosis. <i>Cell Reports</i> , 2017, 18, 213-224.	6.4	38
48	Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence. <i>Multiple Sclerosis Journal</i> , 2017, 23, 300-303.	3.0	6
49	Impaired T-cell migration to the CNS under fingolimod and dimethyl fumarate. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e401.	6.0	24
50	The Self-Inactivating KamiCas9 System for the Editing of CNS Disease Genes. <i>Cell Reports</i> , 2017, 20, 2980-2991.	6.4	96
51	Rivastigmine decreases brain damage in HIV patients with mild cognitive deficits. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 915-920.	3.7	1
52	An unusual case of miliary PML-IRIS in an HIV+ patient. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e370.	6.0	2
53	Increased ex vivo antigen presentation profile of B cells in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 802-809.	3.0	36
54	The Presence of Human Immunodeficiency Virus-Associated Neurocognitive Disorders Is Associated With a Lower Adherence to Combined Antiretroviral Treatment. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx070.	0.9	34

#	ARTICLE	IF	CITATIONS
55	The Combined Quantification and Interpretation of Multiple Quantitative Magnetic Resonance Imaging Metrics Enlightens Longitudinal Changes Compatible with Brain Repair in Relapsing-Remitting Multiple Sclerosis Patients. <i>Frontiers in Neurology</i> , 2017, 8, 506.	2.4	27
56	A New Approach for Deep Gray Matter Analysis Using Partial-Volume Estimation. <i>PLoS ONE</i> , 2016, 11, e0148631.	2.5	7
57	Automated detection of white matter and cortical lesions in early stages of multiple sclerosis. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 43, 1445-1454.	3.4	64
58	327. Genetic Editing for Huntington's Disease. <i>Molecular Therapy</i> , 2016, 24, S131.	8.2	0
59	Rituximab versus fingolimod after natalizumab in multiple sclerosis: Also consider progressive multifocal leukoencephalopathy risk. <i>Annals of Neurology</i> , 2016, 80, 791-791.	5.3	1
60	Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1550-1559.	3.0	202
61	Serum and CSF GQ1b antibodies in isolated ophthalmologic syndromes. <i>Neurology</i> , 2016, 86, 1780-1784.	1.1	14
62	The VZV/IE63-specific T cell response prevents herpes zoster in fingolimod-treated patients. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e209.	6.0	5
63	PML risk stratification using anti-JCV antibody index and L-selectin. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1048-1060.	3.0	62
64	The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. <i>PLoS ONE</i> , 2016, 11, e0152347.	2.5	38
65	Interleukin-22 is increased in multiple sclerosis patients and targets astrocytes. <i>Journal of Neuroinflammation</i> , 2015, 12, 119.	7.2	85
66	Multicontrast MRI Quantification of Focal Inflammation and Degeneration in Multiple Sclerosis. <i>BioMed Research International</i> , 2015, 2015, 1-9.	1.9	16
67	Progressive multifocal leukoencephalopathy in common variable immunodeficiency: mitigated course under mirtazapine and mefloquine. <i>Journal of NeuroVirology</i> , 2015, 21, 694-701.	2.1	22
68	Management of Fulminant Multiple Sclerosis With Rituximab. <i>Neurologist</i> , 2015, 19, 155-157.	0.7	2
69	Acute Lyme Neuroborreliosis With Transient Hemiparesis and Aphasia. <i>Annals of Emergency Medicine</i> , 2015, 66, 60-64.	0.6	5
70	A phase IIa randomized clinical study testing GNBAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients – A twelve month follow-up. <i>Journal of Neuroimmunology</i> , 2015, 285, 68-70.	2.3	41
71	Status epilepticus of inflammatory etiology. <i>Neurology</i> , 2015, 85, 464-470.	1.1	64
72	Environmental factors in multiple sclerosis. <i>Presse Medicale</i> , 2015, 44, e113-e120.	1.9	20

#	ARTICLE	IF	CITATIONS
73	Relapse in herpes simplex virus encephalitis. <i>Neurology</i> , 2015, 85, 1730-1731.	1.1	8
74	CSF lactate for accurate diagnosis of community-acquired bacterial meningitis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 2049-2055.	2.9	35
75	Multicontrast <i>connectometry</i> : A new tool to assess cerebellum alterations in early relapsing-remitting multiple sclerosis. <i>Human Brain Mapping</i> , 2015, 36, 1609-1619.	3.6	30
76	A phase IIa randomised clinical study of GNBAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2015, 21, 885-893.	3.0	53
77	Minimal supportive treatment in natalizumab-related PML in a MS patient. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 354-355.	1.9	6
78	Advanced MRI unravels the nature of tissue alterations in early multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 423-432.	3.7	67
79	MP2RAGE provides new clinically-compatible correlates of mild cognitive deficits in relapsing-remitting multiple sclerosis. <i>Journal of Neurology</i> , 2014, 261, 1606-1613.	3.6	24
80	Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 β -chain (CD11a) in MS patients. <i>Multiple Sclerosis Journal</i> , 2014, 20, 837-842.	3.0	15
81	Immunological Mechanism of Action and Clinical Profile of Disease-Modifying Treatments in Multiple Sclerosis. <i>CNS Drugs</i> , 2014, 28, 535-558.	5.9	26
82	Immune system's role in viral encephalitis. <i>Revue Neurologique</i> , 2014, 170, 577-583.	1.5	4
83	Assessing risks of multiple sclerosis therapies. <i>Journal of the Neurological Sciences</i> , 2013, 332, 59-65.	0.6	8
84	MOBP-specific cellular immune responses are weaker than MOG-specific cellular immune responses in patients with multiple sclerosis and healthy subjects. <i>Neurological Sciences</i> , 2013, 34, 539-543.	1.9	4
85	Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy. <i>Aids</i> , 2013, 27, 203-210.	2.2	23
86	Rivastigmine for HIV-associated neurocognitive disorders. <i>Neurology</i> , 2013, 80, 553-560.	1.1	32
87	A light in the cognitive fog?. <i>Antiviral Therapy</i> , 2013, 18, 149-151.	1.0	2
88	Micro-Structural Brain Alterations in Aviremic HIV+ Patients with Minor Neurocognitive Disorders: A Multi-Contrast Study at High Field. <i>PLoS ONE</i> , 2013, 8, e72547.	2.5	19
89	Impairment of JCV-specific T-cell response by corticotherapy. <i>Neurology</i> , 2012, 79, 2258-2264.	1.1	82
90	Fatal PML associated with efalizumab therapy. <i>Neurology</i> , 2012, 78, 458-467.	1.1	103

#	ARTICLE	IF	CITATIONS
91	Immunological and clinical consequences of treating a patient with natalizumab. <i>Multiple Sclerosis Journal</i> , 2012, 18, 335-344.	3.0	40
92	HLA-B7â€“Restricted EBV-Specific CD8+ T Cells Are Dysregulated in Multiple Sclerosis. <i>Journal of Immunology</i> , 2012, 188, 4671-4680.	0.8	36
93	Type I IFN-mediated regulation of IL-1 production in inflammatory disorders. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 3395-3418.	5.4	32
94	HIV Testing Practices by Clinical Service before and after Revised Testing Guidelines in a Swiss University Hospital. <i>PLoS ONE</i> , 2012, 7, e39299.	2.5	14
95	Multiple Sclerosis Decreases Explicit Counterfactual Processing and Risk Taking in Decision Making. <i>PLoS ONE</i> , 2012, 7, e50718.	2.5	23
96	Vitamin D has a direct immunomodulatory effect on CD8+ T cells of patients with early multiple sclerosis and healthy control subjects. <i>Journal of Neuroimmunology</i> , 2011, 233, 240-244.	2.3	80
97	Type I Interferon Inhibits Interleukin-1 Production and Inflammasome Activation. <i>Immunity</i> , 2011, 34, 213-223.	14.3	810
98	Rituximab is successful in an HIV-positive patient with MuSK myasthenia gravis. <i>Neurology</i> , 2011, 76, 757-758.	1.1	16
99	A promenade along the stream of demyelination. <i>Current Opinion in Neurology</i> , 2010, 23, 203-204.	3.6	0
100	Demyelination as a complication of new immunomodulatory treatments. <i>Current Opinion in Neurology</i> , 2010, 23, 226-233.	3.6	25
101	Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. <i>Aids</i> , 2010, 24, 1243-1250.	2.2	592
102	Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. <i>Lancet Neurology</i> , The, 2010, 9, 264-272.	10.2	86
103	Discrepant findings in immune responses to JC virus in patients receiving natalizumab â€“ Authors' reply. <i>Lancet Neurology</i> , The, 2010, 9, 566-567.	10.2	5
104	Cytokine mRNA profile of Epsteinâ€“Barr virus-stimulated highly differentiated T cells in multiple sclerosis: A pilot study. <i>Journal of Neuroimmunology</i> , 2010, 225, 167-170.	2.3	4
105	Intrathecal immune responses to EBV in early MS. <i>European Journal of Immunology</i> , 2010, 40, 878-887.	2.9	83
106	EFNS guidelines on diagnosis and management of neuromyelitis optica. <i>European Journal of Neurology</i> , 2010, 17, 1019-1032.	3.3	376
107	Elevated Tribbles homolog 2â€“specific antibody levels in narcolepsy patients. <i>Journal of Clinical Investigation</i> , 2010, 120, 713-719.	8.2	263
108	Progressive decline of decision-making performances during multiple sclerosis. <i>Journal of the International Neuropsychological Society</i> , 2009, 15, 291-295.	1.8	25

#	ARTICLE	IF	CITATIONS
109	JC Virus-Specific Immune Responses in Human Immunodeficiency Virus Type 1 Patients with Progressive Multifocal Leukoencephalopathy. <i>Journal of Virology</i> , 2009, 83, 4404-4411.	3.4	74
110	Encephalitis with herpes simplex-2 in the cerebrospinal fluid and anti-RI (ANNA-2) antibodies: an infectious or a paraneoplastic syndrome?. <i>BMJ Case Reports</i> , 2009, 2009, bcr1220081363-bcr1220081363.	0.5	2
111	Inaugural description of Cogan syndrome in an HIV-infected person. <i>Journal of Neurology</i> , 2008, 255, 1427-1428.	3.6	2
112	Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. <i>Brain</i> , 2008, 131, 1712-1721.	7.6	150
113	Chimeric immune receptors (CIRs) specific to JC virus for immunotherapy in progressive multifocal leukoencephalopathy (PML). <i>International Immunology</i> , 2007, 19, 1083-1093.	4.0	14
114	Limbic Encephalitis: Another Example of Molecular Mimicry?. <i>European Neurology</i> , 2007, 57, 191-192.	1.4	2
115	Anaphylactic reaction to methylprednisolone in multiple sclerosis: a practical approach to alternative corticosteroids. <i>Multiple Sclerosis Journal</i> , 2007, 13, 559-560.	3.0	9
116	Neuromyelitis optica following CMV primo-infection. <i>Journal of Internal Medicine</i> , 2007, 261, 500-503.	6.0	32
117	CSF enrichment of highly differentiated CD8+ T cells in early multiple sclerosis. <i>Clinical Immunology</i> , 2007, 123, 105-113.	3.2	57
118	Severe post-EBV encephalopathy associated with myelin oligodendrocyte glycoprotein-specific immune response. <i>Journal of Neuroimmunology</i> , 2007, 192, 192-197.	2.3	7
119	Functional signatures of protective antiviral T cell immunity in human virus infections. <i>Immunological Reviews</i> , 2006, 211, 236-254.	6.0	256
120	JC virus induces a vigorous CD8+ cytotoxic T cell response in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2006, 176, 181-186.	2.3	27
121	Favourable outcome of progressive multifocal leukoencephalopathy in two patients with dermatomyositis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 1079-1082.	1.9	63
122	Interplay of Cellular and Humoral Immune Responses against BK Virus in Kidney Transplant Recipients with Polyomavirus Nephropathy. <i>Journal of Virology</i> , 2006, 80, 3495-3505.	3.4	129
123	Presence of JC virus-specific CTL in the cerebrospinal fluid of PML patients: rationale for immune-based therapeutic strategies. <i>Aids</i> , 2005, 19, 2069-2076.	2.2	36
124	Detection of JC Virus-Specific Cytotoxic T Lymphocytes in Healthy Individuals. <i>Journal of Virology</i> , 2004, 78, 10206-10210.	3.4	78
125	A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. <i>Brain</i> , 2004, 127, 1970-1978.	7.6	188
126	Inflammatory Reaction in Progressive Multifocal Leukoencephalopathy: Harmful or Beneficial?. <i>Journal of NeuroVirology</i> , 2003, 9, 25-31.	2.1	135

#	ARTICLE	IF	CITATIONS
127	The effect of aging on postural stability: a cross sectional and longitudinal study. <i>Neurophysiologie Clinique</i> , 2003, 33, 213-218.	2.2	116
128	Chronic Parkinsonism Associated With Cirrhosis. <i>Archives of Neurology</i> , 2003, 60, 521.	4.5	233
129	Low Frequency of Cytotoxic T Lymphocytes against the Novel HLA-A*0201-Restricted JC Virus Epitope VP1 p36 in Patients with Proven or Possible Progressive Multifocal Leukoencephalopathy. <i>Journal of Virology</i> , 2003, 77, 11918-11926.	3.4	84
130	Association of Prolonged Survival in HLA-A2+ Progressive Multifocal Leukoencephalopathy Patients with a CTL Response Specific for a Commonly Recognized JC Virus Epitope. <i>Journal of Immunology</i> , 2002, 168, 499-504.	0.8	129
131	Persistence of mild parkinsonism 4 months after liver transplantation in patients with preoperative minimal hepatic encephalopathy: a study on neuroradiological and blood manganese changes. <i>Transplant International</i> , 2002, 15, 188-195.	1.6	12
132	JC Virus-Specific Cytotoxic T Lymphocytes in Individuals with Progressive Multifocal Leukoencephalopathy. <i>Journal of Virology</i> , 2001, 75, 3483-3487.	3.4	125
133	Monocular Central Dazzle After Thalamic Infarcts. <i>Journal of Neuro-Ophthalmology</i> , 2000, 20, 97-99.	0.8	8
134	Severe but reversible encephalopathy associated with cefepime. <i>Neurophysiologie Clinique</i> , 2000, 30, 383-386.	2.2	77
135	Magnetic resonance imaging and proton spectroscopic alterations correlate with parkinsonian signs in patients with cirrhosis. <i>Gastroenterology</i> , 2000, 119, 774-781.	1.3	94
136	Periodic downbeat nystagmus. <i>Neurology</i> , 1998, 51, 1478-1480.	1.1	26